Sanofi SA
SNYNF
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Sanofi SA News & Analysis
markets
Globalisation declining? Not in investor portfolios
Morningstar Indexes through a geographic revenue lens.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,207.30 | 32.70 | -0.35% |
CAC 40 | 7,843.04 | 126.65 | -1.59% |
DAX 40 | 24,273.12 | 89.97 | -0.37% |
Dow JONES (US) | 45,282.47 | 349.27 | -0.77% |
FTSE 100 | 9,321.40 | 12.20 | 0.13% |
HKSE | 25,699.09 | 130.82 | -0.51% |
NASDAQ | 21,449.29 | 47.24 | -0.22% |
Nikkei 225 | 42,394.40 | 413.42 | -0.97% |
NZX 50 Index | 12,957.98 | 121.52 | -0.93% |
S&P 500 | 6,439.32 | 27.59 | -0.43% |
S&P/ASX 200 | 8,935.60 | 31.30 | -0.35% |
SSE Composite Index | 3,879.05 | 4.51 | -0.12% |